This accurate, reliable, and fast method of assaying absolute concentrations of phosphate metabolites noninvasively in living tissue, including that of humans, combines 31P nuclear magnetic resonance (NMR) spectroscopy and 1H NMR imaging. The images are used to measure the areas of metabolite-beanng tissue in selected sections through the subject, and31 P spectra are acquired from the same section, together with a concentration reference located on the penphery. Metabolite concentrations are calculated from the ratios of areas and integrated signal intensities. Apparatus and protocol are designed to eliminate corrections due to magnetic field nonuniformities and NMR relaxation times. Mean (and SD) concentrations of adenosine triphosphate (ATP), phosphocreatine, and inorganic phosphate (P1) measured in the brains of 15 normal adult human volunteers with a 1.5-T NMR system were 3.03 (0.49), 5.18 (0.89), and 1.5 (0.7) mmol per liter of wet tissue, respectively. Acquisition times of only a few minutes should facilitate metabolic studies of patients with disorders in limbs and brain, particularly those affecting entire organs.
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AdditIonal Keyphrases: brain
tissue analysis metabolic studies 31P nuclear magnetic resonance (NMR) spectroscopy uniquely provides noninvasive access to high-energy phosphate metabolites in living animals and humans.' The results are conventionally quantified as metabolite ratios, either within a single spectrum or relative to other spectra acquired at different times during an experiment. This representation omits information about absolute metabolite concentrations and can result in ambiguity about which of the metabolites are abnormal or which are changing during the experiment. Moreover, in humans, evidence based on weaker overall 31P NMR signal indicates that phosphate metabolites are reduced in muscular dystrophy (1,2), in the brains of some birth-asphyxiated infants and infants suffering metabolic abnormalities (3, 4), and in chronic adult cerebral infarction (5, 6). Such abnormalities can occur without accompanying changes in metabolite ratios (5) . Thus, non nva8ive measurements of absolute metabolite concentrations not only are of use in research but also may have clinical value.
In the conventional method of measuring human metabolite concentrations in vivo with 31PNMR, spatially localized spectroscopy techniques acquire signals from small, welldefined volumes of tissue, which are then compared with signals from a concentration reference lying outside the sample (7) (8) (9) (10) where the S, V, if,, F, a, and E denote respectively for the metabolite (subscript p) and the standard (subscript s), the integrated NMR signals, the sample volumes, the detection coil sensitivities, the T, saturation factors, the NMR pulse ffip angles, and the signal loss during any delay time ('Pd) before signal detection, owing to (e.g.) missing data points or NMR spin-spin relaxation (T2*) processes (10). The problem is that the final result is severely compromised by systematic and statistical errors in all of the factors in equation 1. We have devised a technique for assaying metabolites in living tissues by NMR that minimizes these systematic errors and provides sufficient NMR sensitivity to permit reduction of the data-acquisition period to several minutes for 31P metabolites on current whole-body NMR spectroscopy machines. Key to the procedure is the recognition that the metabolites in many cross-sections through the head and limbs derive almost totally from brain or muscle tissue, respectively; that the tissue volume in the sections is most precisely determinable noninvasively by 'H NMR imaging; and that metabolite signals derived from whole sections are of much higher sensitivity than those from small selected volumes. This sensitivity improvement can be sacrificed to gain speed, and to eliminate correction factors in equation 1.
Theory
Metabolite quantification proceeds in four simple steps with an NMR instrument capable of both 'H imaging and alp spectroscopy over the subject of interest (11). (a) A 'H image is acquired from a cross-section over which metabolites are to be quantified.
The area of metabolite-bearing tissue in the section, A, is measured. (b) The magnetic field homogeneity is optimized over the section, either by shimming on 'H or 31P spectra from the section itself, or, preferably, by acquiring NMR signals emitted by additional vials of 'H or 31P compound located on the periphery of the section. (c) A 31P concentration reference of area A8 is located in the field-of-view of the section, outside the subject. Its resonance should lie outside the chemical shift range of the metabolites. To minimize the relative error in S8, the concentration of the reference standard, Es],should be such thatS8>>S.(d)A31Pspectrumisacquiredfromthesame whole section as imaged in (a), including the concentration reference, with use of uniform NMR excitation and detection fields, a hard, spatially nonselective, NMR read-out pulse, and 'PR > > 'Pip For example, an NMR pulse sequence comprising a ir NMR pulse in the presence of a gradient perpendicular to the section to selectively invert it, followed by a nonselective n12 pulse ("ir -1712pulse sequence") and immediate data acquisition (Td < <T2*), is suitable. The IT pulse is alternately applied and not applied in consecutive sequence applications, and the resulting signals are subtracted to give the spectrum from the section, as in one-dimensional image-selected in vivo spectroscopy (12). For absolutequantification, this spectroscopysequence has the advantage over a sequence of single slice-selective 171 2 readout pulses ("ii12 pulse sequence") that the Td delay is eliminated.2 The bandwidth of the nonselective 1712pulse and the NMR receiver should at least correspond to the full range of chemical shift dispersion in the section and reference and should not distort resonances from either.
Under conditions of uniform excitation and detection fields, a hard read-out pulse, and long TR, the Js, F a, and E terms in equation 1 can be omitted. Therefore, [p1 in the section is given by:
nuclei vivo (14) .
31P spectra were acquired in 5 mm as averages of 20 free induction decays at 'PR = 15 s, from sections 3 cm thick, above the temple, with use of the IT -(i712) pulse sequence with a 5-ms delay (< <T,) between pulses and immediate acquisition after the i712pulse. The slice-selective gradient was left on during the 5-ms delay to eliminate residual transverse magnetization.
To determine the effect of acquisition delays on metabolite concentration measurements (E in equation 1), we also applied to the same sections of the head a sequence involving 20 slice-selective i712 pulses alone with TR = 15s. Here the delay from the center of the n12pulse to commencement of acquisition was 2.2 ma.
Conventional
'H images were acquired from the same sections from which spectra were derived in about 2 mm. The total patient examination time in the NMR instrument, from ingress to egress, was about 30 min.
All spectra were analyzed by integrating resonances curve-fitted with lorentzian and gaussian lines by using the The field-of-view was accurately calibrated by imaging an array of vials containing water, at known separations. Areas of ventricles partially intersecting the sections were subtracted from brain areas after weighting them for their partial volumes. 
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Materials and Methods
Phosphate metabolites were quantified in the brains of 15 healthy human volunteers, ages 3 1-62 y, with a GE Medical Systems (Milwaukee, WI) 1.5-T Signa body NMR imaging! spectroscopy instrument. A 16-segment quadrature birdcage NMR head coil, 30 cm x 28 cm in diameter and with field uniformity better than 5% across the central plane over the head (13), excited and detected the 31P signals. 'H images were acquired with a conventional quadrature birdcage head-imaging coil. The thickness and location of sections selected by 'H imaging and 3'P spectroscopy are directly proportional to the gyromagnetic ratios of the two 1712pulses require an extra gradient pulse to refocus the NMR signals before detection can commence. occupied less than 13 cm2 (partial volume-weighted) and muscle-tissue areas were less than 7% of those from brains. The brain and ventricles typically constituted 75% of the total section areas, the remainder being dominated by bone and fat, which contribute negligible 3'P metabolite signals. Figure 2 depicts fitted 3'P spectra from a brain section acquired with the selective IT -(i712) sequence. The signalto-noise ratio of /3-ATP was typically about 15 to 20. The amplitude of the reference peak was typically about fourfold that of the brain spectrum. Table 1 Published results for human brain obtained from one to four subjects by the previous 3'P NMR quantification method (8-10) are included in Table! for comparison. Understandably, data from abstracts (8,9) lack a full error analysis.
Measured 3'P metabolite concentrations did not vary significantly with age in this sample (P >0.05). However, mean brain ATP concentrations tended to decrease with increasing age in the data sets acquired by both the selective -(1712) and the selective iiI2 methods (Figure 3) . No other trends were evident.
Discussion
Measured brain metabolite concentrations agree with earlier 3'P NMR determinations within a factor of about 2 (Table 1) Table 1 ). A partial solution to this problem is spectral deconvolution with use of the Fourier transform of a square wave of duration equal to T (15), followed by a line-shapedependent T2* correction (10). Systematic errors in T1 saturation, radiofrequency field homogeneity, and sensitivity factors likely account for other differences in reported metabolite concentrations in human brain (8, 9). These instrument-dependent corrections are, however, avoided al- /kg, respectively (16, 17) . As usual, abnormalities in patients would be detected by statistical testing based on a normal sample with all systematic factors kept constant.
Probably the most serious potential problem afflicting all NMR quantification techniques is inhomogeneity in the main magnetic field across the concentration reference and the tissue being quantified, because this can lead to local disappearance of NMR signals. The practice of shimming on vials located around the head minimizes the likelihood of missing signals near the periphery, where magnet inhomogeneity is usually the worst. Local field disturbances due to metallic implants, for example, are usually detectable in the 'H image, whereasmore subtle inhomogeneity (< < 1 ppm) can be detected by phase-contrast 'H NMR imaging (18,19).
The susceptibility of the ir -(n12) sequence to physiological motions (20) presents no problem if, as is usually the case in brain and limbs, the motion does not result in significant changes in the anatomy of the section.
The new in vivo quantification technique is best suited to global disorders of organs such as dementias and atrophy in brain, or metabolic disorders in muscles. Positron emission tomography shows altered glucose metabolism in brain in dementias and Down's syndrome. Are the concentrations of phosphate metabolites also altered? Are phosphate metabolite concentrations reduced in atrophy, or is there just less brain tissue? Using this technique, we are commencing studies on patients to try to find out.
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